Clinical Trial

Troriluzole in Adult Participants With Spinocerebellar Ataxia

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Protocol Amendment History 52 amendments
This ClinicalTrials.gov record has been amended 52 times since 2018-10-08; most recent amendment 2026-06-07.
Status change: Recruiting → Active, Not Recruiting 2021-02-01
Status change: Not Yet Recruiting → Recruiting 2019-03-07
Trial Details
NCT Number NCT03701399
Lead Sponsor Biohaven Pharmaceuticals, Inc.
Conditions Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Enrollment 299 participants
Start Date 2019-03-08
Primary Completion 2022-02-18 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-24